Euromonitor certification: 44.3% global market share
Leading the industry for 12 consecutive years since 2014

KGC announced on August 31 that its health food brand CheongKwanJang has ranked No. 1 globally in the ginseng and red ginseng retail market and brand share for 12 consecutive years.


According to the 2025 report by global market research firm Euromonitor International, CheongKwanJang achieved a 44.3% share of the world’s ginseng and red ginseng market, based on 2024 sales. The brand has maintained its top position for 12 consecutive years, since such statistics began in 2014.


CheongKwanJang certified No.1 for 12 consecutive years by Euromonitor. Provided by KGC

CheongKwanJang certified No.1 for 12 consecutive years by Euromonitor. Provided by KGC

View original image

In addition, CheongKwanJang secured the No. 1 spot for 12 years in a row in the higher-level category of 'Herbal DS (herbal dietary supplements)' brands, with a market share of 3.5%, further solidifying its reputation as a global comprehensive health food brand.


With 127 years of history and tradition in the red ginseng business, CheongKwanJang continually develops products in line with consumer trends, backed by scientific efficacy research. The company has expanded its consumer base not only in Korea but also through exports to over 40 countries worldwide.


The most popular product is 'HongSamJeong Everytime.' Since its launch in 2012, its cumulative sales have exceeded 1.7 trillion won, and it has consistently generated more than 100 billion won in annual sales as a single product.



A KGC spokesperson stated, “Through the certification by a leading global organization like Euromonitor, CheongKwanJang has once again proven its excellence and competitiveness both domestically and globally. We will continue to strive to become a global comprehensive health food company loved worldwide, based on our differentiated product quality.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing